LifeTech Capital On NBY Catheter Research

LifeTech Capital has released a report regarding the research done by NovaBay Pharmaceuticals NBY on urinary catheter blockage and encrustation. According to the report, ” NovaBay Pharmaceuticals presented a poster on the efficacy of its lead Aganocide NVC-422 the for prevention and treatment for urinary catheter blockage and encrustation (UCBE), which leads to urinary tract infections, at the 2011 Simon Foundation for Continence held in Chicago.” NBY is Buy Rated and has a $4.50 Price Target. NBY closed at $2.24 a share yesterday.